Skip to main content

Table 3 Univariate and multivariate analyses of OS

From: Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy

Variables

Overall survival

Univariate analyses

p

Multivariate analyses

p

Hazara ratios

Hazara ratios

(95%CI)

(95%CI)

Sex

1.067(0.526–2.162)

0.858

  

Age

1.003(0.971–1.035)

0.877

  

BMI

0.989(0.896–1.093)

0.833

  

Smoke

0.877(0.451–1.708)

0.700

  

pT stage

    

 pT2

Ref.

   

 pT3

1.850(1.070–3.197)

0.028

1.382(0.736–2.167)

0.038

 pT4

2.704(1.363–5.364)

0.004

1.945(0.866–3.879)

0.019

NLR

0.215(0.110–0.420)

< 0.001

0.206(0.090–0.472)

< 0.001

PLR

1.290(0.652–2.552)

0.464

  

MLR

0.240(0.109–0.526)

< 0.001

0.509(0.206–1.260)

0.144

Chemotherapy

1.450(0.604–3.482)

0.406

  

Adverse events

0.400(0.187–0.855)

0.018

0.268(0.118–0.610)

0.002

  1. CI Confidence interval, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet-to-lymphocyte ratio, MLR Monocyte-to-lymphocyte ratio, irAEs Immune-related adverse events